Pancreas disorder
MONDO:0002356A non-neoplastic or neoplastic disorder that affects the pancreas. Representative examples of non-neoplastic disorders include pancreatitis and pancreatic insufficiency. Representative examples of neoplastic disorders include cystadenomas, carcinomas, lymphomas, and neuroendocrine neoplasms.
Also known as: disease of pancreas, disease or disorder of pancreas, disorder of pancreas, pancreas disease, pancreas disease or disorder, pancreatic disorder, disease, pancreatic, diseases, pancreatic
4791 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
Disease control TerminatedThis early-phase trial tests a personalized cell therapy for people with metastatic pancreatic cancer. A patient's own T-cells are genetically modified to recognize and attack mesothelin, a protein found on many pancreatic cancer cells. Before receiving the modified cells, patien…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could earlier testing for pregnancy diabetes prevent complications?
Disease control TerminatedThis trial investigates whether screening for gestational diabetes earlier in pregnancy (at 18-20 weeks instead of the usual 24-28 weeks) and providing prompt lifestyle advice and medication if needed can reduce complications such as large babies, C-sections, and high blood press…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a common blood pressure pill boost radiation against tough pancreatic tumors?
Disease control TerminatedThis early-phase study tests whether adding losartan (a blood pressure medicine) to a shorter, higher-dose radiation treatment can help people with pancreatic cancer that is hard to remove surgically. The main goal is to check for side effects and find the safest dose. About 22 a…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug trial offers hope for Hard-to-Treat cancers
Disease control TerminatedThis early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental cancer drug tested in early trial, but study stopped early
Disease control TerminatedThis early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cocktail takes on tough pancreatic cancer
Disease control TerminatedThis early-phase trial is testing whether adding two immunotherapy drugs (botensilimab and balstilimab) to a strong chemotherapy mix plus two oral medications (chloroquine and celecoxib) can help people with metastatic pancreatic cancer that hasn't been treated yet. The study inv…
Phase: PHASE1 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Pancreatic cancer radiation combo trial cut short
Disease control TerminatedThis study looked at whether adding a precise type of radiation (stereotactic body radiation therapy) to standard chemotherapy could better control pancreatic cancer that has spread to only a few spots in the body. The trial planned to enroll patients with limited metastases, but…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hospital metformin debate: keep or stop? small study offers few answers.
Disease control TerminatedThis study looked at whether people with type 2 diabetes should continue taking their usual metformin medication while hospitalized. The goal was to see if it helped control blood sugar, caused stomach issues, or affected how long patients stayed. Only 22 people took part before …
Phase: PHASE4 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a glucose monitor boost diabetes education for newly diagnosed patients?
Disease control TerminatedThis study tested whether using a Freestyle Libre 2 continuous glucose monitor for 28 days, along with standard therapeutic education, helps people recently diagnosed with type 2 diabetes improve their blood sugar control. The trial enrolled 27 adults diagnosed within the past ye…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smartphone system aims to automate insulin delivery for type 1 diabetes
Disease control TerminatedThis study tests an automated insulin delivery system for adults with type 1 diabetes. The system uses a smartphone connected to a continuous glucose monitor and insulin pump to help keep blood sugar levels in a healthy range, especially overnight. Ten participants compare the au…
Phase: NA • Sponsor: Sue Brown • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising drug trial for rare pancreatic cancer stopped early
Disease control TerminatedThis study tested whether the drug surufatinib could help prevent pancreatic neuroendocrine tumors from coming back after surgery. The trial was planned for many participants but was stopped early with only 6 people enrolled. Because it ended early, we don't have clear answers on…
Phase: PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cancer drug BBI-355 trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Heart drug fails to prove benefit for lung failure patients in early-stop trial
Disease control TerminatedThis study tested whether giving the heart medication metoprolol through a vein could help people with severe lung failure (ARDS) in the ICU. The goal was to see if it helped them breathe without a machine for more days. However, the trial was stopped early and only 14 people too…
Phase: PHASE3 • Sponsor: Consorcio Centro de Investigación Biomédica en Red (CIBER) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill targets common cancer mutation in early trial
Disease control TerminatedThis early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The mai…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Pfizer's new cancer pill tested in advanced tumors – study halted early
Disease control TerminatedThis early-stage study tested a new cancer pill (PF-07985045) alone or with other drugs in people with advanced solid tumors that have a KRAS gene mutation. The trial included patients with lung, colon, or pancreatic cancer. The study aimed to check safety and find the right dose…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental diabetes drug trial halted early
Disease control TerminatedThis study tested an experimental drug called TOL-3021 in people with type 1 diabetes to see if it could help preserve the body's ability to produce insulin. The trial enrolled 78 participants aged 12 to 41 who had been diagnosed within the last 5 years. The study was terminated …
Phase: PHASE2 • Sponsor: Tolerion, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental cell therapy targets tough cancers, but trial ends early
Disease control TerminatedThis early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointesti…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Diabetes drug trial halted: could BMF-219 have boosted insulin?
Disease control TerminatedThis study tested an experimental drug called BMF-219 in people with type 1 diabetes to see if it could help their bodies produce more insulin. The trial was stopped early, but researchers planned to compare insulin levels between those who got the drug and those who got a placeb…
Phase: PHASE2 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental cancer pill targets genetic weakness in Hard-to-Treat tumors
Disease control TerminatedThis study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo trial for tough pancreatic cancer shows early promise
Disease control TerminatedThis early-stage trial tested a combination of two drugs, trametinib and hydroxychloroquine, in 25 adults with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and understand side effects. The study was stopped early, so r…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
CRISPR's diabetes cell therapy trial ends early
Disease control TerminatedThis early-stage study tested a new treatment called VCTX211 for people with type 1 diabetes. The goal was to see if implanting these special cells could help the body make insulin and reduce the need for insulin shots. Only 5 people took part, and the study was stopped early. Th…
Phase: PHASE1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising diabetes delay study halted due to lack of participants
Disease control TerminatedThis study tested a low dose of a drug called ATG to see if it could delay or prevent type 1 diabetes in people at high risk. Only 2 people enrolled, so the study was stopped early. The goal was to measure how long it took for participants to develop full-blown diabetes.
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Meals and exercise program aimed at managing diabetes in pregnancy
Disease control TerminatedThis study tested a community-based program called Meals 4 Moms for pregnant women with gestational diabetes. Participants received tailored meals, education, and activity monitoring. The goal was to see if the program was practical and acceptable. Only 8 women were enrolled befo…
Phase: NA • Sponsor: UConn Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Cancer combo trial halted early: what we learned
Disease control TerminatedThis study tested a combination of two drugs, donafenib and KN046, in people with advanced gastrointestinal cancers that had not responded to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The trial was stopped early, and only 15 peopl…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Tailored cancer therapy put to the test
Disease control TerminatedThis study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Diabetes drug adherence study halted after just one participant
Disease control TerminatedThis study aimed to see if following the exact dosing instructions for oral semaglutide helps control blood sugar in people with type 2 diabetes who are already on metformin. Only one person enrolled before the study was stopped early. The main focus was on changes in blood sugar…
Sponsor: Aalborg University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental diabetes drug AP026 tested in early trial – but study halted
Disease control TerminatedThis early-stage trial tested a new drug called AP026, a fusion protein that targets two pathways (GLP-1 and FGF21) to potentially treat type 2 diabetes. The study planned to enroll 74 healthy adults but was terminated early after only 14 participants. The main goal was to check …
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Pfizer's new cancer drug combo tested in tiny early trial
Disease control TerminatedThis early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental combo shot for pancreatic cancer stalls after just 2 patients
Disease control TerminatedThis very early trial tested two immune-stimulating drugs injected directly into tumors for people with stage IV pancreatic cancer. The goal was to see if the combination could shrink tumors or slow their growth. However, the study was stopped early after enrolling only 2 partici…
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Pazopanib dose hunt in frail seniors halted early
Disease control TerminatedThis phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…
Phase: PHASE1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Surgery for spread pancreatic cancer? small trial halted early
Disease control TerminatedThis study tested whether surgically removing both the main pancreatic tumor and any limited spread to the liver or lungs could help people with pancreatic cancer live longer. Only 5 people enrolled before the trial was stopped early. Participants first received chemotherapy, the…
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can cutting carbs and a diabetes drug help kidneys?
Disease control TerminatedThis small pilot study tested whether a low-carb diet (50-100 grams of carbs per day) combined with the diabetes drug dapagliflozin could improve blood sugar control in people with chronic kidney disease and prediabetes or type 2 diabetes. Four participants were split into two gr…
Phase: NA • Sponsor: Department of Nephrology Clinic Ottakring Vienna • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo tackles pancreatic cancer resistance – but study halted early
Disease control TerminatedThis study tested whether combining two drugs, trametinib and hydroxychloroquine, could help overcome treatment resistance in people with advanced pancreatic cancer that had spread. The trial aimed to see how many patients were free of cancer growth after 12 weeks. It included 20…
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New antibody drug tested in patients with advanced stomach and gut cancers
Disease control TerminatedThis early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals …
Phase: PHASE1 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Cancer combo trial ends before it begins: only one patient enrolled
Disease control TerminatedThis early-phase trial aimed to test the safety of combining two drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study planned to include patients with certain breast, ovarian, pancreatic, and lung canc…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Chemo cocktail aimed at zapping pancreatic cysts
Disease control TerminatedThis study tested whether injecting chemotherapy drugs directly into pancreatic cysts could shrink or eliminate them. It involved 75 adults with cysts between 2-5 cm. The approach used an endoscope to guide the injection, comparing two different pre-treatment rinses. The trial wa…
Phase: PHASE3 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Radioactive microparticles injected into pancreatic tumors: a new hope?
Disease control TerminatedThis study aimed to see if injecting radioactive particles (OncoSil) directly into pancreatic tumors during an endoscopic ultrasound, combined with chemotherapy, could safely shrink tumors and improve survival. It was designed for people with advanced pancreatic cancer that could…
Phase: PHASE2, PHASE3 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental KRAS blocker tested in advanced cancers – trial halted early
Disease control TerminatedThis early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cet…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Plant-Based diet shows promise for diabetes remission in new study
Disease control TerminatedThis study looked at whether a plant-based diet and lifestyle changes could help people with type 2 diabetes, prediabetes, or obesity improve their health. Researchers aimed for diabetes remission (normal blood sugar without medication for at least 3 months) or significant weight…
Phase: NA • Sponsor: National Council of Scientific and Technical Research, Argentina • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Cancer drug olaparib tested for rare pancreatic tumor
Disease control TerminatedThis phase 2 trial tested the drug olaparib (Lynparza) in people with advanced pancreatic acinar cell carcinoma, a rare pancreatic cancer. Participants took olaparib pills twice daily for up to 2 years. The study was terminated early after enrolling only 5 people, so it is not kn…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental cancer drug DCC-3084 tested in early trial
Disease control TerminatedThis early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…
Phase: PHASE1 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can a common diabetes drug shield transplanted kidneys?
Disease control TerminatedThis study tested the drug empagliflozin (a diabetes medicine) in 20 people who had a kidney transplant, some with type 2 diabetes and some without. The goal was to see if the drug could help protect their heart and kidney function. The trial was stopped early, so the findings ar…
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Probiotic study for diabetes and COPD halted early
Disease control TerminatedThis study looked at whether taking probiotics alongside regular treatment could help lower blood sugar and improve lung function in people with both type 2 diabetes and chronic obstructive pulmonary disease (COPD). The trial planned to enroll 30 adults aged 50-85, but it was ter…
Phase: NA • Sponsor: Glac Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a viagra drug help fight liver cancer? new trial tests unlikely combo
Disease control TerminatedThis phase 2 trial tested a combination of three drugs—nivolumab (an immunotherapy), tadalafil (commonly used for erectile dysfunction), and vancomycin (an antibiotic)—in adults with liver cancer or liver metastases from colorectal or pancreatic cancers that had not responded to …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental diabetes drug trial halted early – what happened?
Disease control TerminatedThis study tested a new drug called CK-0045 in 90 adults with type 2 diabetes and overweight or obesity. Participants received weekly injections of CK-0045 or a placebo for 16 weeks to see if it improved blood sugar after meals and reduced body weight. The trial was terminated ea…
Phase: PHASE2 • Sponsor: Cytoki Pharma • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New tech approach aims to prevent repeat hospital stays for diabetes patients
Disease control TerminatedThis study tested whether a team-based approach using continuous glucose monitors could help adults with type 1 diabetes better control their blood sugar and avoid another hospital stay after a diabetic ketoacidosis (DKA) episode. Only 2 people enrolled before the study was stopp…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Pancreatic cancer drug trial halted after just two patients
Disease control TerminatedThis phase 2 trial aimed to see if the drug niraparib could shrink tumors in people with metastatic pancreatic cancer that has certain gene mutations. Only 2 patients were enrolled before the study was terminated early, so we don't have enough information to know if it works. The…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could a new drug help preserve insulin production in type 1 diabetes?
Disease control TerminatedThis early-stage trial tested four different doses of siplizumab in 8 people aged 8–45 who were diagnosed with type 1 diabetes within the past 18 months. The goal was to find a safe dose that changes certain immune cell patterns linked to better insulin production. Participants r…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Engineered immune cells take on Hard-to-Treat gut cancers
Disease control TerminatedThis early-phase study tested a new treatment called LCAR-G08, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells in the gut. The study included 17 adults with advanced colorectal, stomach, pancreatic, or small bowel …
Phase: PHASE1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Diabetes drug liraglutide may fight fatty liver, but trial halted early
Disease control TerminatedThis study looked at whether liraglutide, a diabetes drug, can reduce liver fat and improve cholesterol in people with type 2 diabetes. It involved 127 patients who took liraglutide for 6 months, with liver fat measured by MRI. However, the trial was terminated early, so the full…
Phase: PHASE4 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental drug BI 765883 tested in pancreatic cancer – early trial ends
Disease control TerminatedThis early study tested an experimental drug called BI 765883, alone or with chemotherapy, in 8 adults with advanced pancreatic cancer. The goal was to find a safe dose and see if it helps shrink tumors. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on pancreatic cancer in early trial
Disease control TerminatedThis early-phase study tested a treatment called huCART-meso cells, which are a patient's own immune cells modified to recognize and attack pancreatic cancer cells. The trial included 54 people with advanced pancreatic cancer that could not be removed by surgery. The main goal wa…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug combo for Hard-to-Treat cancers shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…
Phase: PHASE1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental pancreatic cancer combo trial halted early
Disease control TerminatedThis study tested an experimental drug called APG-1387 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer. The goal was to find the safest dose and see if the combination could shrink tumors. However, the trial was termi…
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Does longer glucose monitoring help diabetes control? small study halted early
Disease control TerminatedThis study aimed to see if using a professional continuous glucose monitor (CGM) for 6 months, instead of 3 months, helps people with poorly controlled type 2 diabetes (who don't use insulin) spend more time with healthy blood sugar levels. Only 12 participants were enrolled befo…
Phase: NA • Sponsor: East Tennessee State University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Promising cancer drug trial halted early: what happened?
Disease control TerminatedThis study tested a drug called Promitil in 19 people with ovarian or pancreatic cancer that had specific gene mutations (BRCA or HRD) and had stopped responding to first treatment. The goal was to see if Promitil could control tumor growth safely. The trial was terminated early,…
Phase: PHASE2 • Sponsor: Lipomedix Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Vitamin-Like supplement tested for diabetic nerve pain – but trial stopped early
Disease control TerminatedThis early-phase trial tested whether nicotinamide riboside (a form of vitamin B3 sold as Niagen) could help repair nerve damage in people with type 2 diabetes or prediabetes. Only 10 participants were enrolled before the study was terminated. The main goal was to measure changes…
Phase: PHASE1, PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental radioactive therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-stage study tested a radioactive drug called 177Lu-FF58 in 24 people with advanced pancreatic, gastroesophageal, or brain cancer. The drug seeks out and attaches to specific proteins on cancer cells to deliver radiation directly. The main goals were to check safety, fi…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Digital diabetes coach put to the test – but trial ends early
Disease control TerminatedThis study tested a digital system called 'Live well with type 2 diabetes' to help people manage their condition. It compared the digital program to usual care for 138 adults recently diagnosed with type 2 diabetes. The main goal was to see if it improved blood sugar levels. Howe…
Phase: NA • Sponsor: Region Jönköping County • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental drug aims to save Insulin-Making cells in newly diagnosed type 1 diabetes
Disease control TerminatedThis Phase 2 trial tested an oral drug called ladarixin in 141 people aged 14-45 recently diagnosed with type 1 diabetes. The goal was to see if ladarixin could preserve the body's ability to produce insulin by protecting beta cells. The study was terminated early, so while it ma…
Phase: PHASE2 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Experimental combo for tough pancreatic cancer shows early promise
Disease control TerminatedThis early-phase trial tested whether adding the experimental drug YL-13027 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe for people with advanced pancreatic cancer that no longer responds to treatment. Only 4 participants were enrolled before the study was st…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Cancer combo trial halted early – what went wrong?
Disease control TerminatedThis phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Early scope procedure fails to show clear benefit in severe pancreatitis trial
Disease control TerminatedThis study tested whether doing an early endoscopic ultrasound and removing any gallstones from the bile duct could help people with severe pancreatitis caused by gallstones. The trial planned to enroll many patients but was stopped early after only 27 participants. The main goal…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental pancreatic cancer combo trial halted early
Disease control TerminatedThis early-phase study tested whether adding the experimental drug NIS793 to standard chemotherapy (FOLFIRINOX) could help people with metastatic pancreatic cancer. Only 4 people took part before the study was stopped. The goal was to find a safe dose and see if the combination c…
Phase: PHASE1 • Sponsor: Colin D. Weekes, M.D., PhD • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Pancreatic cancer drug trial halted after safety issues
Disease control TerminatedThis trial tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it helped shrink tumors. The study was stopped early because of unexpected safety problems that reappeare…
Phase: PHASE1, PHASE2 • Sponsor: SOTIO Biotech a.s. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
AI-Powered diabetes coach could replace some doctor visits
Disease control TerminatedThis study tested a software called DreaMed Advisor Pro that automatically analyzes blood sugar and insulin pump data to suggest insulin dose adjustments. About 100 people with type 1 diabetes (ages 6-30) were split into two groups: one received recommendations directly from the …
Phase: NA • Sponsor: Rabin Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental drug combo for pancreatic cancer shows early promise, but trial halted
Disease control TerminatedThis early-phase trial tested a drug called CPI-613 (devimistat) combined with chemotherapy and radiation for people with pancreatic cancer that cannot be surgically removed. The goal was to find the safest dose. Only 8 people took part before the study was stopped. While the app…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Cancer drug trial halted midway: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer-Fighting super cells tested in solid tumors – study halted early
Disease control TerminatedThis study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…
Phase: PHASE1, PHASE2 • Sponsor: Alaunos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Phase: PHASE1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Pancreatic cancer combo trial halted after just one patient
Disease control TerminatedThis study aimed to see if adding the experimental drug BNT321 to standard chemotherapy (mFOLFIRINOX) after surgery could help prevent pancreatic cancer from coming back. It was designed for people whose tumors were fully removed. However, the trial was stopped early after enroll…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control TerminatedThis study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…
Phase: PHASE2 • Sponsor: Tempus AI • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug ASP2074 trial halted early
Disease control TerminatedThis early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Actym Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Promising pancreatic cancer combo trial halted early
Disease control TerminatedThis study tested whether adding the experimental drugs NIS793 (with or without spartalizumab) to standard chemotherapy could help people with metastatic pancreatic cancer that had not been treated before. The trial enrolled 164 adults and aimed to see if the combinations slowed …
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental cancer drug AMG 199 tested in patients with stomach, colon, and pancreatic tumors
Disease control TerminatedThis early-phase study tested an experimental drug called AMG 199 in adults with advanced stomach, gastroesophageal junction, colorectal, or pancreatic cancers that have a specific protein (MUC17). The main goals were to check safety and find the best dose. The study was stopped …
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug targets genetic weakness in tough cancers
Disease control TerminatedThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental drug targets Hard-to-Treat cancers in new trial
Disease control TerminatedThis phase 2 trial tested a drug called tusamitamab ravtansine, alone or with chemotherapy (gemcitabine), in 50 people with advanced breast or pancreatic cancers that have a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors. The study was terminated e…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Heart drug for diabetics shows promise but trial ends early
Disease control TerminatedThis study tested whether pemafibrate, a drug that lowers triglycerides, could reduce heart attacks, strokes, and heart-related deaths in over 10,000 people with type 2 diabetes and high triglycerides. Participants took either pemafibrate or a placebo twice daily. The trial was t…
Phase: PHASE3 • Sponsor: Kowa Research Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Cancer combo trial halted early: what we know
Disease control TerminatedThis phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…
Phase: PHASE2 • Sponsor: BioMed Valley Discoveries, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental cancer pill targets Hard-to-Treat gene mutations
Disease control TerminatedThis early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…
Phase: PHASE1 • Sponsor: Ikena Oncology • Aim: Disease control
Last updated Jun 26, 2026 19:17 UTC
-
New cancer drug LB4330 tested in early trial
Disease control TerminatedThis early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…
Phase: PHASE1 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated Jun 26, 2026 16:51 UTC
-
Insulin showdown: toujeo vs tresiba for diabetics with kidney disease
Disease control TerminatedThis study compared two long-acting insulins, Toujeo and Tresiba, in people with type 2 diabetes who also have kidney problems and had never used insulin before. The goal was to see which one controls blood sugar better and causes fewer low blood sugar events. The trial was stopp…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 14:43 UTC
-
New drug combo tested for Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors such as head and neck or gastrointestinal cancers. The study aimed to find safe doses and check for early signs of effectiveness. It …
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 26, 2026 12:43 UTC
-
New automated insulin system tested in tiny trial
Disease control TerminatedThis study tested a system that automatically adjusts insulin delivery using a continuous glucose monitor, a smartphone app, and an insulin pump. It aimed to see if the system could help adults with type 1 diabetes spend more time with their blood sugar in a healthy range. Only o…
Phase: NA • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 26, 2026 12:39 UTC
-
Blood test may spot pancreatic cancer without needle biopsy
Diagnosis TerminatedThis study looked at whether a blood test that detects circulating tumor cells (CTCs) could diagnose pancreatic cancer. Researchers planned to compare the blood test results with standard tissue biopsies in 101 people with pancreatic tumors. The trial was terminated early, so the…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New imaging agent aims to spot Hard-to-Find cancers
Diagnosis TerminatedThis early-phase trial tested a radioactive imaging agent called 68Ga-FF58 in 14 adults with certain advanced solid tumors (glioblastoma, brain metastases from breast cancer, gastroesophageal cancer, or pancreatic cancer). The goal was to see if the agent could help detect these …
Phase: EARLY_PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
Smartwatch aims to replace finger pricks and cuffs
Diagnosis TerminatedThis Mayo Clinic study tested a special smartwatch that uses light sensors to measure blood glucose, blood pressure, and heart signals. The goal was to see if the watch could give accurate readings compared to standard methods like finger-stick tests and blood pressure cuffs. The…
Phase: NA • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
Yoghurt study aimed to curb diabetes risk, but ended early
Prevention TerminatedThis study tested whether eating yoghurt daily for 24 weeks could improve blood sugar control in adults with prediabetes (high risk for type 2 diabetes). Only 8 people enrolled, and the study was stopped early, so no firm conclusions can be drawn. The goal was to see if a simple …
Phase: NA • Sponsor: Danone Global Research & Innovation Center • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
Diabetes education tailored for hispanic men shows promise in small study
Symptom relief TerminatedThis study tested whether a five-week culturally tailored diabetes education program could help Hispanic men aged 18-64 with type 2 diabetes improve their self-management behaviors like healthy eating, physical activity, and medication use. The program was designed specifically f…
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can a simple ear massage help cancer patients eat better?
Symptom relief TerminatedThis small pilot study tested whether applying acupressure to the ear could help improve appetite and prevent weight loss in people with advanced stomach, esophagus, or pancreatic cancer. The approach uses small adhesive pellets placed on specific ear spots to stimulate the nervo…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Can a short daily workout help hospitalized diabetes patients?
Symptom relief TerminatedThis study tested whether hospitalized adults with type 2 diabetes or prediabetes could safely do 30 minutes of resistance training each day. The goal was to see if this exercise routine is feasible and if it helps control blood sugar and prevent muscle loss during a hospital sta…
Phase: PHASE1 • Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New study tests safer pain relief for kids with pancreatitis
Symptom relief TerminatedThis study tested whether using less opioids for initial pain relief in children with acute pancreatitis is as effective and safer than the usual opioid-first approach. It involved 23 children at Boston Children's Hospital. The goal was to gather data for a larger future trial.
Phase: PHASE2 • Sponsor: Boston Children's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Mood drug trial for pancreatic cancer patients halted early
Symptom relief TerminatedThis study tested whether the antidepressant escitalopram could reduce depression in people with localized pancreatic or related cancers who were receiving chemotherapy before surgery. Only 4 participants enrolled before the trial was stopped. The goal was to measure changes in d…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Radiation plus chemo for pancreatic cancer pain: trial ends early
Symptom relief TerminatedThis phase 2 trial tested whether adding MR-guided radiation to standard chemotherapy could reduce pain in people with metastatic pancreatic cancer. Only 9 participants were enrolled before the study was terminated early. The main goal was to track pain scores over time, but the …
Phase: PHASE2 • Sponsor: Ludwig-Maximilians - University of Munich • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
New drug aimed at easing diabetic nerve pain hits roadblock
Symptom relief TerminatedThis study tested an experimental drug called GSK3858279 in 147 adults with chronic nerve pain from diabetes. The goal was to see if it could reduce pain better than a placebo. However, the trial was terminated early, so we have less information than planned.
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Weight-Loss drug trial for pancreatic cancer halted early
Symptom relief TerminatedThis study tested a drug called anamorelin to see if it could help prevent weight loss and improve appetite in people with advanced pancreatic cancer who were starting chemotherapy. The trial planned to include about 100 participants but was stopped early after only 4 people enro…
Phase: PHASE2 • Sponsor: Lahey Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Diabetes and antibiotics: a risky mix for the heart?
Knowledge-focused TerminatedThis study looks at how high blood sugar combined with a medication called moxifloxacin (an antibiotic known to affect heart rhythm) impacts the heart's electrical activity in people with insulin-resistant type 2 diabetes. Researchers will measure changes in heart tracings (ECGs)…
Phase: NA • Sponsor: Richmond Pharmacology Limited • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Tiny nerves may explain chronic cough in diabetes
Knowledge-focused TerminatedThis study looked at whether people with type 2 diabetes who have a chronic cough also have damage to small nerves in their skin. Researchers compared diabetic patients with and without chronic cough using nerve tests and skin biopsies. The study was terminated early with only 7 …
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Can pictures help patients understand research better?
Knowledge-focused TerminatedThis study tested whether a visual consent form with pictures helps patients with cancer or Alzheimer's understand research better than standard text. Researchers planned to enroll 266 adults across three U.S. sites. The trial was terminated early, so results may be limited.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Pancreatic cancer gene study targets muscle wasting
Knowledge-focused TerminatedThis pilot study aimed to find genetic differences, called microRNAs, that might explain why some pancreatic cancer patients lose muscle mass (cachexia). Researchers planned to analyze tumor samples from 40 patients undergoing surgery, focusing on African Americans who may be at …
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Heartburn drug tested against pancreatic cancer in early trial
Knowledge-focused TerminatedThis early-phase study tested whether high doses of omeprazole, a common heartburn medication, could safely change certain markers in pancreatic tumors. The trial planned to enroll 25 patients with exocrine pancreatic cancer who were scheduled for surgery. Participants took omepr…
Phase: EARLY_PHASE1 • Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists probe hidden danger of low blood sugar in diabetes
Knowledge-focused TerminatedThis study looked at why people with type 1 diabetes often fail to sense dangerously low blood sugar (hypoglycemia). Researchers tested how opioid drugs like morphine and naloxone affect the body's ability to respond to low sugar. The goal was to better understand the problem, no…
Phase: PHASE2 • Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Blood markers may forecast diabetes cure after gastric bypass
Knowledge-focused TerminatedThis study aimed to find blood and tissue markers that could predict whether obese patients with type 2 diabetes would go into remission after bariatric surgery. Researchers planned to measure 9 specific molecules in blood samples and also collect fat and muscle tissue during sur…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Mental health study aims to uncover Long-Term heart risks
Knowledge-focused TerminatedThis study followed 167 adults with mental health issues like anxiety, depression, or sleep problems who visited their primary care doctor. Researchers used health conversations and a blood test to track lifestyle changes and heart disease risks over up to 20 years. The goal was …
Phase: NA • Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Hidden fat lumps may sabotage insulin: new study investigates
Knowledge-focused TerminatedThis study looked at whether small, hard-to-see fat lumps under the skin (called subclinical lipohypertrophy) change how insulin is absorbed in people with diabetes. Researchers planned to enroll 20 adults with type 1 or type 2 diabetes who use insulin and had these hidden lumps.…
Phase: NA • Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Virtual reality could help measure and treat cancer pain, study suggests
Knowledge-focused TerminatedThis study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
When you eat matters: stanford study tests meal timing for better blood sugar and sleep
Knowledge-focused TerminatedThis Stanford study looked at how changing when and what you eat affects blood sugar, body temperature, and sleep in people with prediabetes, type 2 diabetes, and healthy adults. Participants followed different meal-timing schedules, like eating within a 10-hour window starting e…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Gut microbiome study in kids with autoimmune diseases ends early
Knowledge-focused TerminatedThis study aimed to compare the gut bacteria of children newly diagnosed with juvenile idiopathic arthritis, type 1 diabetes, or inflammatory bowel disease with those of their healthy siblings. Researchers wanted to see if differences in gut microbes and diet could explain why so…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Small study tests blood sugar targets to prevent lows during exercise in type 1 diabetes
Knowledge-focused TerminatedThis study looked at people with type 1 diabetes who use do-it-yourself automated insulin delivery (DIY-AID) systems. Researchers wanted to find the best blood glucose target to set 60 minutes before moderate aerobic exercise (like cycling) to keep blood sugar stable and avoid da…
Phase: NA • Sponsor: Institut de Recherches Cliniques de Montreal • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Free diabetes classes for latinos aim to uncover health barriers
Knowledge-focused TerminatedThis study looked at Latino adults with diabetes who attended free education classes. Researchers collected information about their health habits, blood sugar levels, and barriers to medical care. The goal was to better understand the needs of this community, not to test a new tr…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Diabetes Drug's heart benefits probed in tiny, terminated study
Knowledge-focused TerminatedThis study aimed to see how dapagliflozin, a diabetes drug, affects blood vessel health in people with type 2 diabetes. Researchers planned to measure blood pressure and other markers of vascular function. However, the trial was terminated early and only enrolled 4 participants, …
Phase: PHASE4 • Sponsor: Boston University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Can your personality change your diabetes genes?
Knowledge-focused TerminatedThis study looked at whether people with type 1 or type 2 diabetes who have a 'Type A' (impatient, proactive) or 'Type B' (calm, slow) personality show different genetic markers linked to inflammation and stress. Researchers planned to collect blood samples and have participants …
Phase: NA • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Diabetes drug may alter your taste buds and food desires
Knowledge-focused TerminatedThis study looked at how the diabetes medication Liraglutide (Victoza) affects taste, food cravings, and eating habits in people with type 2 diabetes who are overweight. Researchers compared three groups: patients starting Liraglutide, diabetic patients not on the drug, and healt…
Phase: PHASE4 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Cancer gene hunt: could tumor maps guide better GI cancer treatment?
Knowledge-focused TerminatedThis study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Cystic fibrosis study aims to build a research database, not test a cure
Knowledge-focused TerminatedThis study is for people with cystic fibrosis and their family members. Its goal is to collect medical information and biological samples during regular clinic visits. These will be stored and used by researchers to learn more about how cystic fibrosis affects the body and how it…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Liquid biopsy study halted: did it help guide cancer care?
Knowledge-focused TerminatedThis study aimed to see if a simple blood test (liquid biopsy) could help doctors make better treatment decisions for people with advanced cancers of the colon, pancreas, or bile duct. Researchers planned to enroll about 130 participants but stopped early with only 16 enrolled. T…
Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Early eating study for diabetes ends early
Knowledge-focused TerminatedThis study looked at whether eating most calories before 2 PM could help control blood sugar in people with type 2 diabetes. It planned to enroll 10 participants but was terminated after only 2 joined. The goal was to compare early eating with a typical eating pattern over six da…
Phase: NA • Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Timing delivery for gestational diabetes: What's the safest week?
Knowledge-focused TerminatedThis study aimed to find the best time (between 37 and 39 weeks of pregnancy) to deliver babies of women with poorly controlled gestational diabetes. Researchers planned to enroll up to 3,450 pregnant women but stopped early with 304 participants. The goal was to see which delive…
Phase: NA • Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Can a Stick-On sensor replace finger pricks before surgery?
Knowledge-focused TerminatedThis pilot study tested whether continuous glucose monitors (CGMs) could be used in the days before and after surgery to track blood sugar in people with diabetes. Researchers placed a CGM sensor on 22 patients during a preoperative visit and compared its readings to standard fin…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
New urine test could reveal if diabetes patients are taking their pills
Knowledge-focused TerminatedThis study aimed to see if a new urine test can accurately tell whether people with type 2 diabetes are taking their medications as prescribed. Researchers planned to compare the urine test results with standard methods like questionnaires and pharmacy records in 90 participants.…
Sponsor: University of Leicester • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Tablet teaching for diabetes: a High-Tech hope for new patients?
Knowledge-focused TerminatedThis study tested whether using a bedside tablet with interactive education modules helps people newly diagnosed with type 1 diabetes learn more than standard paper-based materials. The trial planned to enroll 28 patients but was terminated early. Researchers measured diabetes kn…
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Can a fitness watch help kids with diabetes get moving?
Knowledge-focused TerminatedThis study looked at whether wearing a Garmin Vivosmart activity tracker could increase physical activity and improve diabetes control in children and young adults (ages 8-21) with Type 1 Diabetes. Participants wore the tracker for a year and completed surveys about their diabete…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
New study checks if sugar sensors work in sick newborns
Knowledge-focused TerminatedThis study looked at how accurate Dexcom G6 continuous glucose monitors are for newborns with hyperinsulinism, a condition causing low blood sugar. One baby wore the sensor on their thigh for 10 days in the NICU. Researchers compared the sensor's readings with standard blood suga…
Sponsor: MemorialCare Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Study on arthritis and diabetes link halted early
Knowledge-focused TerminatedThis study looked at whether people with both rheumatoid arthritis and type 2 diabetes have a harder time controlling their diabetes than those with osteoarthritis and diabetes. Researchers planned to follow 176 adults to see how quickly they needed new diabetes treatments. Howev…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:07 UTC
-
New E-Health system aims to keep tabs on chronic patients remotely
Knowledge-focused TerminatedThis pilot study tested an e-health system that uses tele-monitoring, tele-notification, and tele-coaching to help manage adults with at least two chronic conditions like heart failure, COPD, or diabetes. The goal was to see how well the system could detect health problems early.…
Phase: NA • Sponsor: Air Liquide Santé International • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:48 UTC
-
Can two old drugs stop a dangerous diabetes complication?
Knowledge-focused TerminatedThis study tested whether two medications, naloxone (a nasal spray) and diazoxide (an oral pill), could prevent the body from losing its ability to sense low blood sugar—a condition called hypoglycemia unawareness. Only 4 healthy volunteers were enrolled before the trial was stop…
Phase: PHASE4 • Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:35 UTC